TNBC, TRIPLE NEGATIVE BREAST CANCER
Clinical trials for TNBC, TRIPLE NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new TNBC, TRIPLE NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on aggressive breast cancer brain tumors shows promise in early trial
Disease control Recruiting nowThis study tests whether combining radiation therapy with three drugs (platinum chemotherapy, adebrelimab, and bevacizumab) can control brain metastases from triple-negative breast cancer. About 58 adults aged 18-70 with this specific type of advanced breast cancer will receive t…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug BAL0891 enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail targets rare breast cancer that defies standard treatment
Disease control Recruiting nowThis phase 2 trial is testing a combination of three drugs—alpelisib, L-NMMA, and nab-paclitaxel—in people with a rare, aggressive form of breast cancer called metaplastic breast cancer (MpBC) that has spread or is locally advanced. The study aims to find the best dose and see if…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New cocktail of drugs hopes to tackle tough breast cancer
Disease control Recruiting nowThis phase II trial is testing a combination of three drugs—QL1706 (an immunotherapy), anlotinib (a targeted therapy), and nab-paclitaxel (chemotherapy)—as a first treatment for advanced triple-negative breast cancer. The study will enroll 34 women and aims to see if the combo ca…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Eczema drug shows promise in breast cancer trial
Disease control Recruiting nowThis early-phase trial is testing whether adding dupilumab (an eczema and asthma drug) to standard immunotherapy and chemotherapy can safely improve outcomes for people with locally advanced triple-negative breast cancer. About 15 participants will receive the combination before …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Rima Patel • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Last-Resort drug access opens for aggressive breast cancer patients
Disease control AVAILABLEThis program provides early access to an experimental drug called leronlimab for people with advanced triple-negative breast cancer who have run out of standard treatments. Participants must be adults with stage IIIB or IV cancer that has worsened despite prior therapy. The goal …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New triple therapy aims to boost immune attack on aggressive breast cancer
Disease control Recruiting nowThis study tests whether adding a drug that blocks a certain immune cell (CSF-1R inhibitor) and radiation to standard immunotherapy (pembrolizumab) can help the body fight high-risk triple-negative breast cancer more effectively. About 35 women with this aggressive cancer will re…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Stephen Shiao • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug combo shows promise in early breast cancer trial
Disease control Recruiting nowThis study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery. …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental injection aims to boost Chemo's punch in aggressive breast cancer
Disease control Recruiting nowThis phase 2 trial tests whether injecting the experimental drug INT230-6 directly into the tumor before standard chemotherapy and immunotherapy can improve outcomes for people with early triple-negative breast cancer (TNBC). About 61 participants will be randomly assigned to rec…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo aims to turn Chemo-Resistant breast cancer curable
Disease control Recruiting nowThis study tests a new approach for people with triple-negative breast cancer whose tumors don't shrink after standard chemotherapy. Participants receive targeted radiation to the tumor followed by immunotherapy (toripalimab) plus more chemo. The goal is to see if this combinatio…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Radioactive 'Smart Bomb' targets cancer in new human trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy aims to boost immune response in hard-to-treat breast cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 adul…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Triple attack: radiation, immunotherapy, and chemo take on tough breast cancer
Disease control Recruiting nowThis study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer (TNBC). TNBC is harder to treat than other breast cancers, and this combination aims to boost the im…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Promising triple-drug combo aims to wipe out aggressive breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding two targeted drugs (sintilimab and bevacizumab) to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 37 women with stage II-III disease. The main goal is to see how many patients have no cancer left at s…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo attack on aggressive breast cancer shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for women with triple-negative breast cancer. About 35 participants will receive the combination, then undergo surgery. The main goal is to…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
MRI-Guided chemo reduction trial aims to spare TNBC patients from toxic drugs
Disease control Recruiting nowThis study tests whether MRI scans can identify triple-negative breast cancer patients who respond well to initial chemotherapy and immunotherapy, allowing them to skip the second, more toxic phase of treatment. About 54 participants will receive four cycles of a chemo-immunother…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo aims to boost breast cancer remission before surgery
Disease control Recruiting nowThis early-phase study tests a new immunotherapy drug (QL1706) combined with short cycles of chemotherapy in 30 people with early-stage triple-negative breast cancer. The goal is to see if this approach can eliminate all signs of cancer before surgery. Participants receive either…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Light-Based device could predict chemo success in breast cancer
Diagnosis Recruiting nowThis study tests a new imaging system that uses light to monitor how breast cancer responds to chemotherapy before surgery. Researchers want to see if it can accurately predict when the cancer is completely gone. The study involves 15 women with specific types of breast cancer. I…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Indiana University • Aim: Diagnosis
Last updated Jun 27, 2026 09:06 UTC
-
New mammogram method could replace costly MRI for breast cancer patients
Diagnosis Recruiting nowThis study compares a special contrast-enhanced mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether breast cancer has been eliminated by chemotherapy. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms durin…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Alison Stopeck • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
New study seeks to improve quality of life for advanced breast cancer patients
Symptom relief Recruiting nowThis study tracks how patients with metastatic triple-negative breast cancer feel during treatment with sacituzumab govitecan or standard chemotherapy. Researchers will measure changes in quality of life and symptoms using patient questionnaires. The goal is to see which treatmen…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Live biopsy study aims to predict immunotherapy response in cancer patients
Knowledge-focused Recruiting nowThis study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Simple blood test could predict breast cancer return
Knowledge-focused Recruiting nowThis study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Breast cancer trial aims to match drugs to tumors for personalized care
Knowledge-focused Recruiting nowThis study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Blood test could predict immunotherapy outcomes for aggressive breast cancer
Knowledge-focused Recruiting nowThis study is for women with triple-negative breast cancer, either early-stage or advanced, who are receiving immunotherapy. Researchers want to see if changes in a simple blood marker called CRP can predict how well the treatment works. The goal is to find a way to personalize t…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC